{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:38:16Z","timestamp":1753889896300,"version":"3.41.2"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["clinical-practice-and-epidemiology-in-mental-health.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["CPEMH"],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:sec>\n          <jats:title>Background<\/jats:title>\n          <jats:p>Many pharmacological treatments are considered effective in the treatment of panic disorder (PD), however, about 20 to 40% of the patients have treatment-resistant PD. Pharmacogenetics could explain why some patients are treatment-resistant.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>Objective<\/jats:title>\n          <jats:p>Our objective was to gather preliminary data on the clinical usefulness of pharmacogenetic testing in this disorder.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>Methods<\/jats:title>\n          <jats:p>Twenty patients with treatment-resistant PD were included in this observational study and submitted to commercial pharmacogenetic testing. Testing panel included gene polymorphisms related to CYP, genes <jats:italic>EPHX1<\/jats:italic>, <jats:italic>UGT1A4<\/jats:italic>, <jats:italic>UGT2B15<\/jats:italic>, <jats:italic>ABCB1<\/jats:italic>, <jats:italic>ADRA2A<\/jats:italic>, <jats:italic>ANKK1<\/jats:italic>, <jats:italic>COMT<\/jats:italic>, <jats:italic>DRD2<\/jats:italic>, <jats:italic>FKBP5<\/jats:italic>, <jats:italic>GRIK4<\/jats:italic>, <jats:italic>GSK3B<\/jats:italic>, <jats:italic>HTR1A<\/jats:italic>, <jats:italic>HTR2A<\/jats:italic>, <jats:italic>HTR2C<\/jats:italic>, <jats:italic>MC4R<\/jats:italic>, <jats:italic>OPRM1<\/jats:italic>, <jats:italic>SCN1A<\/jats:italic>, <jats:italic>SLC6A4<\/jats:italic> and <jats:italic>MTHFR<\/jats:italic>. Participants received treatment-as-usual for PD before being enrolled in this study, including first-line and second-line medications for PD.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>Results<\/jats:title>\n          <jats:p>In 30% of the patients, the tests indicated reduced chance of response to the prescribed drug, while they indicated very low serum levels of the prescribed drug in 20% of the subjects. The pharmacogenetic tests predicted reduction of MTHFR enzyme activity in 74% of the patients. ABCB1 gene alleles associated to drug resistance were found in 90% of the samples.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>Conclusion<\/jats:title>\n          <jats:p>Commercial pharmacogenetic testing failed to predict negative treatment outcome in most patients with PD. The association between treatment-resistance in PD and the genes CYP2C19, MTHFR and ABCB1 deserves further study.<\/jats:p>\n      <\/jats:sec>","DOI":"10.2174\/0117450179337258241031035148","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:17:01Z","timestamp":1733224621000},"update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis"],"prefix":"10.2174","volume":"20","author":[{"given":"Marcos","family":"Fidry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morena Mourao","family":"Zugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Costa","family":"do Cabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renan Machado","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuella Assad","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Gitahy Falc\u00e3o","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Egidio","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3875-4601","authenticated-orcid":true,"given":"Rafael C.","family":"Freire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"Baldwin D.S.","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, et al. \n          Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the british association for psychopharmacology. \n          J Psychopharmacol  \n          2014; \n          28\n          (5)\n          : 403-39.","journal-title":"J. Psychopharmacol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"Katzman M.A.","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, et al. \n          Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. \n          BMC Psychiatry  \n          2014; \n          14\n          (1)\n          : S1.","journal-title":"BMC Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/15622975.2022.2086295","volume":"24","author":"Bandelow B.","year":"2023","unstructured":"Bandelow B, Allgulander C, Baldwin DS, et al. \n          World federation of societies of biological psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders \u2013 Version 3. Part I: Anxiety disorders. \n          World J Biol Psychiatry  \n          2023; \n          24\n          (2)\n          : 79-117.","journal-title":"World J. Biol. Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1017\/S1092852900022379","volume":"9","author":"Bandelow B.","year":"2004","unstructured":"Bandelow B, R\u00fcther E. \n          Treatment-resistant panic disorder. \n          CNS Spectr  \n          2004; \n          9\n          (10)\n          : 725-39.","journal-title":"CNS Spectr."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1517\/14656566.2011.562200","volume":"12","author":"Freire R.C.","year":"2011","unstructured":"Freire RC, Hallak JE, Crippa JA, Nardi AE. \n          New treatment options for panic disorder: Clinical trials from 2000 to 2010. \n          Expert Opin Pharmacother  \n          2011; \n          12\n          (9)\n          : 1419-28.","journal-title":"Expert Opin. Pharmacother."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"CD010676","DOI":"10.1002\/14651858.CD010676.pub2","volume":"2018","author":"Bighelli I.","year":"2018","unstructured":"Bighelli I, Castellazzi M, Cipriani A, et al. \n          Antidepressants versus placebo for panic disorder in adults. \n          Cochrane Libr  \n          2018; \n          2018\n          (4)\n          : CD010676.","journal-title":"Cochrane Libr."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/da.22525","volume":"33","author":"Patterson B.","year":"2016","unstructured":"Patterson B, Ameringen VM. \n          Augmentation strategies for treatment-resistant anxiety disorders: A systematic review and meta-analysis. \n          Depress Anxiety  \n          2016; \n          33\n          (8)\n          : 728-36.","journal-title":"Depress. Anxiety"},{"key":"ref8","unstructured":"Freire RC, Zugliani MM, Garcia RF, Nardi AE. \n          Pharmacological and non-pharmacological approaches for treatment-resistant panic disorder.\n          Panic disorder: Assessment, management, and research insights  \n          \n          \n          \n          2018; \n          169-93."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14656566.2016.1109628","volume":"17","author":"Freire R.C.","year":"2016","unstructured":"Freire RC, Zugliani MM, Garcia RF, Nardi AE. \n          Treatment\u2013resistant panic disorder: A systematic review. \n          Expert Opin Pharmacother  \n          2016; \n          17\n          (2)\n          : 159-68.","journal-title":"Expert Opin. Pharmacother."},{"key":"ref10","first-page":"48","volume":"4","author":"Holt R.L.","year":"2007","unstructured":"Holt RL, Lydiard RB. \n          Management of treatment-resistant panic disorder. \n          Psychiatry  \n          2007; \n          4\n          (10)\n          : 48-59.","journal-title":"Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1744-9081-3-41","volume":"3","author":"Blaya C.","year":"2007","unstructured":"Blaya C, Salum GA, Lima MS, Segal LS, Manfro GG. \n          Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and panic disorder: A systematic review and meta-analysis. \n          Behav Brain Funct  \n          2007; \n          3\n          (1)\n          : 41.","journal-title":"Behav. Brain Funct."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/jmg.2010.086876","volume":"48","author":"Schumacher J.","year":"2011","unstructured":"Schumacher J, Kristensen AS, Wendland JR, N\u00f6then MM, Mors O, McMahon FJ. \n          The genetics of panic disorder. \n          J Med Genet  \n          2011; \n          48\n          (6)\n          : 361-8.","journal-title":"J. Med. Genet."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ajmg.1320540411","volume":"54","author":"Neale M.C.","year":"1994","unstructured":"Neale MC, Walters EE, Eaves LJ, Kessler RC, Heath AC, Kendler KS. \n          Genetics of blood\u2010injury fears and phobias: A population\u2010based twin study. \n          Am J Med Genet  \n          1994; \n          54\n          (4)\n          : 326-34.","journal-title":"Am. J. Med. Genet."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.neulet.2004.04.010","volume":"363","author":"Rothe C.","year":"2004","unstructured":"Rothe C, Koszycki D, Bradwejn J, et al. \n          Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. \n          Neurosci Lett  \n          2004; \n          363\n          (3)\n          : 276-9.","journal-title":"Neurosci. Lett."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ajmg.b.30773","volume":"150B","author":"Hodges L.M.","year":"2009","unstructured":"Hodges LM, Weissman MM, Haghighi F, et al. \n          Association and linkage analysis of candidate genes GRP, GRPR, CRHR1, and TACR1 in panic disorder. \n          Am J Med Genet B Neuropsychiatr Genet  \n          2009; \n          150B\n          (1)\n          : 65-73.","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2217\/pgs.15.66","volume":"16","author":"Caldirola D.","year":"2015","unstructured":"Caldirola D, Perna G. \n          Is there a role for pharmacogenetics in the treatment of panic disorder? \n          Pharmacogenomics  \n          2015; \n          16\n          (8)\n          : 771-4.","journal-title":"Pharmacogenomics"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"134443","DOI":"10.1016\/j.neulet.2019.134443","volume":"726","author":"McGowan O.O.","year":"2020","unstructured":"McGowan OO. \n          Pharmacogenetics of anxiety disorders. \n          Neurosci Lett  \n          2020; \n          726\n          : 134443.","journal-title":"Neurosci. Lett."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/17425255.2021.1991912","volume":"17","author":"Clavel S.M.","year":"2021","unstructured":"Clavel SM, Weber H, Deckert J, Lehmann EA. \n          The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics. \n          Expert Opin Drug Metab Toxicol  \n          2021; \n          17\n          (11)\n          : 1249-60.","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/humu.22970","volume":"37","author":"Froese D.S.","year":"2016","unstructured":"Froese DS, Huemer M, Suormala T, et al. \n          Mutation update and review of severe methylenetetrahydrofolate reductase deficiency. \n          Hum Mutat  \n          2016; \n          37\n          (5)\n          : 427-38.","journal-title":"Hum. Mutat."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41398-018-0276-6","volume":"8","author":"Wan L.","year":"2018","unstructured":"Wan L, Li Y, Zhang Z, Sun Z, He Y, Li R. \n          Methylenetetrahydro-folate reductase and psychiatric diseases. \n          Transl Psychiatry  \n          2018; \n          8\n          (1)\n          : 242.","journal-title":"Transl. Psychiatry"},{"key":"ref21","first-page":"48","volume":"15","author":"Anderson S","year":"2016","unstructured":"Anderson S, Panka J, Rakobitsch R, Tyre K, Pulliam K. \n          Anxiety and methylenetetrahydrofolate reductase mutation treated with S-adenosyl methionine and methylated B vitamins. \n          Integr Med  \n          2016; \n          15\n          (2)\n          : 48-52.","journal-title":"Integr. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/archpsyc.60.6.618","volume":"60","author":"Bjelland I.","year":"2003","unstructured":"Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. \n          Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: The hordaland homocysteine study. \n          Arch Gen Psychiatry  \n          2003; \n          60\n          (6)\n          : 618-26.","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4088\/JCP.v65n0811","volume":"65","author":"Papakostas G.I.","year":"2004","unstructured":"Papakostas GI, Petersen T, Mischoulon D, et al. \n          Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: Predictors of relapse during the continuation phase of pharmacotherapy. \n          J Clin Psychiatry  \n          2004; \n          65\n          (8)\n          : 1096-8.","journal-title":"J. Clin. Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1176\/appi.ajp.2012.11071114","volume":"169","author":"Papakostas G.I.","year":"2012","unstructured":"Papakostas GI, Shelton RC, Zajecka JM, et al. \n          L-methylfolate as adjunctive therapy for SSRI-resistant major depression: Results of two randomized, double-blind, parallel-sequential trials. \n          Am J Psychiatry  \n          2012; \n          169\n          (12)\n          : 1267-74.","journal-title":"Am. J. Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/JCP.0000000000001014","volume":"39","author":"He Q.","year":"2019","unstructured":"He Q, Mei Y, Liu Y, et al. \n          Effects of cytochrome P450 2C19 genetic polymorphisms on responses to escitalopram and levels of brain-derived neurotrophic factor in patients with panic disorder. \n          J Clin Psychopharmacol  \n          2019; \n          39\n          (2)\n          : 117-23.","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","volume":"32","author":"Fukasawa T.","year":"2007","unstructured":"Fukasawa T, Suzuki A, Otani K. \n          Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. \n          J Clin Pharm Ther  \n          2007; \n          32\n          (4)\n          : 333-41.","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1176\/ajp.153.3.311","volume":"153","author":"Nemeroff C.B.","year":"1996","unstructured":"Nemeroff CB, DeVane CL, Pollock BG. \n          Newer antidepressants and the cytochrome P450 system. \n          Am J Psychiatry  \n          1996; \n          153\n          (3)\n          : 311-20.","journal-title":"Am. J. Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e82562","DOI":"10.1371\/journal.pone.0082562","volume":"8","author":"Preissner S.C.","year":"2013","unstructured":"Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S. \n          Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. \n          PLoS One  \n          2013; \n          8\n          (12)\n          : e82562.","journal-title":"PLoS One"},{"key":"ref29","first-page":"e146","volume":"20","author":"Fagerness J.","year":"2014","unstructured":"Fagerness J, Fonseca E, Hess GP, et al. \n          Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. \n          Am J Manag Care  \n          2014; \n          20\n          (5)\n          : e146-56.","journal-title":"Am. J. Manag. Care"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1176\/appi.ajp.2015.14050680","volume":"172","author":"Schatzberg A.F.","year":"2015","unstructured":"Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM. \n          ABCB1 genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. \n          Am J Psychiatry  \n          2015; \n          172\n          (8)\n          : 751-9.","journal-title":"Am. J. Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1590\/S1516-44462000000300003","volume":"22","author":"Amorim P.","year":"2000","unstructured":"Amorim P. \n          Mini international neuropsychiatric interview (MINI): Validation of a short structured diagnostic psychiatric interview. \n          Rev Bras Psiquiatr  \n          2000; \n          22\n          (3)\n          : 106-15.","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00004850-199506000-00003","volume":"10","author":"Bandelow B.","year":"1995","unstructured":"Bandelow B. \n          Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The panic and agoraphobia scale. \n          Int Clin Psychopharmacol  \n          1995; \n          10\n          (2)\n          : 73-82.","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","volume":"56","author":"Beck A.T.","year":"1988","unstructured":"Beck AT, Epstein N, Brown G, Steer RA. \n          An inventory for measuring clinical anxiety: Psychometric properties. \n          J Consult Clin Psychol  \n          1988; \n          56\n          (6)\n          : 893-7.","journal-title":"J. Consult. Clin. Psychol."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Beck AT, Steer RA, Brown GK. \n          Manual for the beck depression inventory-II \n          \n          \n          1996.","DOI":"10.1037\/t00742-000"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Guy W. \n          ECDEU assessment manual for psychopharmacology, revised \n          \n          \n          1976.","DOI":"10.1037\/e591322011-001"},{"key":"ref36","unstructured":"PHARMGKB. \n          Clinical annotation levels of evidence. \n          \n          2021.\n         Available from: https:\/\/www.pharmgkb.org\/page\/clinAnnLevels"},{"key":"ref37","unstructured":"PHARMGKB. \n            VIPs: Very important pharmacogenes. \n          \n          2020.\n         Available from: https:\/\/www.pharmgkb.org\/vips"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pcn.12275","volume":"69","author":"Inada T.","year":"2015","unstructured":"Inada T, Inagaki A. \n          Psychotropic dose equivalence in J apan. \n          Psychiatry Clin Neurosci  \n          2015; \n          69\n          (8)\n          : 440-7.","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pcn.13195","volume":"75","author":"Takeshima M.","year":"2021","unstructured":"Takeshima M, Otsubo T, Funada D, et al. \n          Does cognitive behavioral therapy for anxiety disorders assist the discontinuation of benzodiazepines among patients with anxiety disorders? A systematic review and meta\u2010analysis. \n          Psychiatry Clin Neurosci  \n          2021; \n          75\n          (4)\n          : 119-27.","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2350-12-13","volume":"12","author":"Santos P.C.J.L.","year":"2011","unstructured":"Santos PCJL, Soares RAG, Santos DBG, et al. \n          CYP2C19 and ABCB1gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. \n          BMC Med Genet  \n          2011; \n          12\n          (1)\n          : 13.","journal-title":"BMC Med. Genet."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41397-018-0015-7","volume":"18","author":"Soares R.F.","year":"2018","unstructured":"Soares RF, Kehdy FSG, Coelho SJ, et al. \n          Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: A RIBEF\/EPIGEN-Brazil initiative. \n          Pharmacogenomics J  \n          2018; \n          18\n          (6)\n          : 749-59.","journal-title":"Pharmacogenomics J."},{"key":"ref42","first-page":"216","volume":"13","author":"Miller A.L.","year":"2008","unstructured":"Miller AL. \n          The methylation, neurotransmitter, and antioxidant connections between folate and depression. \n          Altern Med Rev  \n          2008; \n          13\n          (3)\n          : 216-26.","journal-title":"Altern. Med. Rev."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.4088\/JCP.v65n0810","volume":"65","author":"Papakostas G.I.","year":"2004","unstructured":"Papakostas GI, Petersen T, Mischoulon D, et al. \n          Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: Predictors of clinical response in fluoxetine-resistant depression. \n          J Clin Psychiatry  \n          2004; \n          65\n          (8)\n          : 1090-5.","journal-title":"J. Clin. Psychiatry"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2020.01.096","volume":"267","author":"Zheng W.","year":"2020","unstructured":"Zheng W, Li W, Qi H, et al. \n          Adjunctive folate for major mental disorders: A systematic review. \n          J Affect Disord  \n          2020; \n          267\n          : 123-30.","journal-title":"J. Affect. Disord."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/14622416.9.3.267","volume":"9","author":"Estrela R.C.E.","year":"2008","unstructured":"Estrela RCE, Ribeiro FS, Carvalho RS, et al. \n          Distribution of ABCB1 polymorphisms among Brazilians: Impact of population admixture. \n          Pharmacogenomics  \n          2008; \n          9\n          (3)\n          : 267-76.","journal-title":"Pharmacogenomics"},{"key":"ref46","unstructured":"US Food and Drug Administration. \n        \tTable of pharmacogenomic biomarkers in drug labeling. \n          \n          2024.\n         Available from: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling"}],"container-title":["Clinical Practice &amp; Epidemiology in Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V20\/e17450179337258\/e17450179337258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V20\/e17450179337258\/e17450179337258.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V20\/e17450179337258\/e17450179337258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:17:14Z","timestamp":1733224634000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/VOLUME\/20\/ELOCATOR\/e17450179337258\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.2174\/0117450179337258241031035148","relation":{},"ISSN":["1745-0179"],"issn-type":[{"type":"print","value":"1745-0179"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"0000-0003-3875-4601","URL":"0000-0003-3875-4601","order":0,"name":"orcid","label":"ORCID","group":{"name":"identifiers","label":"Identifiers"}},{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e17450179337258"}}